Walleye Capital LLC Has $1.31 Million Stock Holdings in Tyra Biosciences, Inc. $TYRA

Key Points

• Walleye Capital LLC increased its stake in Tyra Biosciences by 123.5%, now owning $1.31 million worth of shares after acquiring an additional 77,762 shares in the first quarter.
• Several hedge funds have also increased their positions in Tyra Biosciences, with AlphaQuest LLC showing the largest increase at 489.7%.
• Tyra Biosciences received favorable analyst ratings, including an "overweight" rating from Piper Sandler, with a consensus target price of $30.83.

Walleye Capital LLC increased its position in Tyra Biosciences, Inc. (NASDAQ:TYRA - Free Report) by 123.5% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 140,742 shares of the company's stock after acquiring an additional 77,762 shares during the quarter. Walleye Capital LLC owned about 0.27% of Tyra Biosciences worth $1,309,000 at the end of the most recent quarter.

Other institutional investors have also recently bought and sold shares of the company. BNP Paribas Financial Markets bought a new position in Tyra Biosciences in the 4th quarter worth $60,000. Two Sigma Advisers LP acquired a new stake in Tyra Biosciences in the 4th quarter worth $171,000. Deutsche Bank AG grew its position in Tyra Biosciences by 52.0% in the 4th quarter. Deutsche Bank AG now owns 18,909 shares of the company's stock worth $263,000 after purchasing an additional 6,466 shares during the last quarter. Bank of America Corp DE grew its position in Tyra Biosciences by 21.7% in the 4th quarter. Bank of America Corp DE now owns 66,157 shares of the company's stock worth $920,000 after purchasing an additional 11,804 shares during the last quarter. Finally, Exchange Traded Concepts LLC grew its position in Tyra Biosciences by 42.7% in the 1st quarter. Exchange Traded Concepts LLC now owns 11,861 shares of the company's stock worth $110,000 after purchasing an additional 3,550 shares during the last quarter. Institutional investors own 84.14% of the company's stock.

Tyra Biosciences Stock Down 1.1%

NASDAQ:TYRA traded down $0.14 on Tuesday, reaching $12.53. The stock had a trading volume of 419,862 shares, compared to its average volume of 302,272. The company has a market capitalization of $667.81 million, a P/E ratio of -7.04 and a beta of 1.09. Tyra Biosciences, Inc. has a 1-year low of $6.42 and a 1-year high of $29.60. The stock has a fifty day moving average price of $10.73 and a 200-day moving average price of $10.27.

Tyra Biosciences (NASDAQ:TYRA - Get Free Report) last announced its earnings results on Thursday, August 14th. The company reported ($0.47) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.53) by $0.06. Sell-side analysts predict that Tyra Biosciences, Inc. will post -1.57 earnings per share for the current fiscal year.

Analysts Set New Price Targets

TYRA has been the topic of several research analyst reports. HC Wainwright restated a "buy" rating and issued a $30.00 price target on shares of Tyra Biosciences in a research report on Friday, August 22nd. Piper Sandler initiated coverage on shares of Tyra Biosciences in a research report on Wednesday, May 21st. They issued an "overweight" rating and a $33.00 price target on the stock. Six analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the company currently has a consensus rating of "Buy" and an average target price of $30.83.

Insider Activity

In other news, Director Gilla Kaplan sold 30,000 shares of the company's stock in a transaction that occurred on Thursday, June 12th. The shares were sold at an average price of $10.31, for a total transaction of $309,300.00. Following the transaction, the director directly owned 59,623 shares in the company, valued at approximately $614,713.13. This represents a 33.47% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders have sold 61,392 shares of company stock worth $628,358 in the last quarter. 15.20% of the stock is currently owned by corporate insiders.

Tyra Biosciences Company Profile

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.